Stada Arzneimittel AG (SAZ) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers a portfolio of products in various therapeutic categories including pain, womens health, cardiovascular conditions and diabetes. Few of its major generic products include including Tilidin Naloxon, Atorvastatin, Pantoprazol, Epoetin zeta and Diclofenac. Its major branded products include APO-Go, Grippostad, Snup, Fultium, and Vitaprost. The company operates in more than 30 countries with sales in Germany, Central Europe, CIS/Eastern Europe and Asia-Pacific. STADA is headquartered in Bad Vilbel, Germany.

Stada Arzneimittel AG (SAZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Stada Arzneimittel AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Stada Arzneimittel Acquires Nizoral from Janssen Pharma 15
STADA Arzneimittel Acquires AndroDoz and NeroDoz from OOO PharmEnergy for USD7.9 Million 16
Thornton & Ross Acquires Rights for Flexitol from LaCorium Health for USD17 Million 17
STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For US$108 Million 18
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 19
Private Equity 21
Ardian May Sell Riemser Pharma for USD494.3 Million 21
Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 23
Bain Capital Private Equity and Cinven Partners Renew the Terms to Acquire Stada Arzneimittel 25
Partnerships 27
Enzymatica Enters into Distribution Agreement with STADA for ColdZyme 27
Theratechnologies Enters into Commercialization Agreement with BL&H 28
Stada Arzneimittel to Form Joint Venture with Hetero Drugs 29
Claris Lifesciences Enters into Distribution Agreement with Stada Arzneimittel 30
Licensing Agreements 31
BL&H Enters into Licensing Agreement with Race Oncology 31
BL&H Enter into Licensing Agreement with MDNA Life Sciences 32
Thornton & Ross Enters into Licensing Agreement with Futura Medical 33
BL&H Enters into Licensing Agreement with Telesta Therapeutics 34
STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 35
Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 36
Stada Arzneimittel Enters into Licensing Agreement with Richter-Helm BioTec 37
Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 38
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 40
Equity Offering 41
Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 41
Debt Offering 42
Stada Arzneimittel Announces Private Placement of Bonds Due 2022 for USD325.5 42
Stada Arzneimittel Completes Private Placement Of Bonds Due 2018 For US$452 Million 43
Asset Transactions 44
DMN Invest Acquires Two Drug Manufacturing Facilities From Stada Arzneimittel 44
Acquisition 45
Nidda Healthcare to Acquire Stake in Stada Arzneimittel 45
Elliott Management May Acquire Stake in Stada Arzneimittel 46
STADA Arzneimittel to Acquire Laboratorio Vannier for USD13 Million 47
STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 48
Stada Arzneimittel Completes Acquisition Of Thornton & Ross, OTC Drug Maker, For US$339 Million 49
Sun Pharma Mulls Acquisition Of Stada Arzneimittel 51
Stada Arzneimittel AG - Key Competitors 52
Stada Arzneimittel AG - Key Employees 53
Stada Arzneimittel AG - Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Recent Developments 56
Financial Announcements 56
May 03, 2018: STADA with solid business development in the first quarter of 2018 56
Mar 08, 2018: STADA records positive business development in 2017 58
Nov 09, 2017: STADA shows good business development in the third quarter of 2017 and the first nine months 61
Corporate Communications 63
Apr 16, 2018: Changes in the management team of STADA 63
Feb 01, 2018: Supervisory Board of STADA Arzneimittel appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018 64
Feb 01, 2018: Peter Goldschmidt to succeed Claudio Albrecht as CEO on 1 September 2018 65
Jul 04, 2017: STADA Arzneimittel appoints new Chief Executive Officer and Chief Financial Officer incumbents step down from their positions 66
Apr 24, 2017: Dr. Ralph Grobecker to become Managing Director of STADAs OTC segment 67
Other Significant Developments 68
Mar 08, 2018: CEO Albrecht to modernize STADA Biosimilars to focus on oncology, CNS, diabetes and ophthalmology 68
Aug 03, 2017: STADA shows good operational development in first six months of 2017 69
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List Of Tables

List of Tables
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Stada Arzneimittel AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Stada Arzneimittel AG, Deals By Therapy Area, 2012 to YTD 2018 10
Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Stada Arzneimittel Acquires Nizoral from Janssen Pharma 15
STADA Arzneimittel Acquires AndroDoz and NeroDoz from OOO PharmEnergy for USD7.9 Million 16
Thornton & Ross Acquires Rights for Flexitol from LaCorium Health for USD17 Million 17
STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For US$108 Million 18
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 19
Ardian May Sell Riemser Pharma for USD494.3 Million 21
Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 23
Bain Capital Private Equity and Cinven Partners Renew the Terms to Acquire Stada Arzneimittel 25
Enzymatica Enters into Distribution Agreement with STADA for ColdZyme 27
Theratechnologies Enters into Commercialization Agreement with BL&H 28
Stada Arzneimittel to Form Joint Venture with Hetero Drugs 29
Claris Lifesciences Enters into Distribution Agreement with Stada Arzneimittel 30
BL&H Enters into Licensing Agreement with Race Oncology 31
BL&H Enter into Licensing Agreement with MDNA Life Sciences 32
Thornton & Ross Enters into Licensing Agreement with Futura Medical 33
BL&H Enters into Licensing Agreement with Telesta Therapeutics 34
STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 35
Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 36
Stada Arzneimittel Enters into Licensing Agreement with Richter-Helm BioTec 37
Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 38
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 40
Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 41
Stada Arzneimittel Announces Private Placement of Bonds Due 2022 for USD325.5 42
Stada Arzneimittel Completes Private Placement Of Bonds Due 2018 For US$452 Million 43
DMN Invest Acquires Two Drug Manufacturing Facilities From Stada Arzneimittel 44
Nidda Healthcare to Acquire Stake in Stada Arzneimittel 45
Elliott Management May Acquire Stake in Stada Arzneimittel 46
STADA Arzneimittel to Acquire Laboratorio Vannier for USD13 Million 47
STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 48
Stada Arzneimittel Completes Acquisition Of Thornton & Ross, OTC Drug Maker, For US$339 Million 49
Sun Pharma Mulls Acquisition Of Stada Arzneimittel 51
Stada Arzneimittel AG, Key Competitors 52
Stada Arzneimittel AG, Key Employees 53
Stada Arzneimittel AG, Subsidiaries 54

List Of Figures

List of Figures
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 12

Stada Arzneimittel AG (SAZ) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are

USD 250 View Report

Stada Arzneimittel AG Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Stada Arzneimittel AG Company Profile is a detailed strategic and analytical report on Stada Arzneimittel AG. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Stada Arzneimittel AG Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Stada Arzneimittel AG Company Profile is a detailed strategic and analytical report on Stada Arzneimittel AG. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Stada Arzneimittel AG (SAZ) - Medical Equipment - Deals and Alliances Profile

Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available